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Abstract The complement system is best known for its role
in innate immunity, providing a first line of defence against
infection, maintaining tissue homeostasis by flagging apopto-
tic cells and debris for removal, and orchestrating crosstalk
between adaptive and innate immunity. In a growing number
of diseases, complement is known to drive pathogenesis or to
contribute as an inflammatory amplifier of a disease trigger.
Association of complement with common and devastating
diseases has driven an upsurge in complement drug discovery,
but despite a wealth of knowledge in the complexities of the
cascade, and many decades of effort, very few drugs have
progressed to late-stage clinical studies. The reasons for this
are becoming clear with difficulties including high target con-
centration and turnover, lack of clarity around disease mech-
anism and unwanted side effects. Lessons learnt from drugs
which are either approved, or are currently in late-stage devel-
opment, or have failed and dropped off the drug development
landscape, have been invaluable to drive a new generation of
innovative drugs which are progressing through clinical de-
velopment. In this review, the challenges associated with com-
plement drug discovery are discussed and the current drug
development landscape is reviewed. The latest approaches to
improve drug characteristics are explored and those agents
which employ these technologies to improve accessibility to
patients are highlighted.
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The complement system is best known for its role in innate
immunity, providing a first line of defence against infection,
facilitating phagocytic uptake of pathogens and in some cases
directly killing pathogens or infected cells through lysis. The
highly inflammatory mediators generated as a by-product of
activation play a crucial part in signalling to surrounding cells
and to migrating leukocytes that there is danger in the envi-
ronment [1, 2]. Complement also plays a key role in tissue
homeostasis, flagging apoptotic cells and debris for removal,
guiding immune complexes to the reticuloendothelial system
for clearance, and orchestrating crosstalk between adaptive
and innate immunity. Unfortunately, complement contributes
to pathogenesis in a number of diseases; in some cases, it
drives pathology, in others it amplifies or exacerbates the in-
flammatory and damaging impact of non-complement disease
triggers. Despite a wealth of knowledge in the complexities of
the complement cascade, and many decades of endeavour,
very few drugs have progressed in clinical studies. Recently,
strong genetic associations of complement with common dis-
eases have emerged and fuelled the fire of complement drug
discovery leading to an explosion in complement therapies in
development; whilst many of these agents and others before
them have failed to progress, their legacy is key to future
success. The drug development landscape is now littered with
dead or dying assets that perfectly exemplify the challenges
associated with ‘drugging’ the complement system. This re-
view will briefly scan the current drug development landscape
and focus on the challenges of complement drug discovery
The original version of this article was revised due to a retrospective Open
Access order.
This article is a contribution to the special issue on Complement in Health
and Disease: Novel Aspects and Insights - Guest Editors: Paul Morgan
and David Kavanagh
* Claire L. Harris
claire.harris@newcastle.ac.uk
1 Complement Therapeutics Research Group and National Renal
Complement Therapeutics Centre, Institute of Cellular Medicine,
Newcastle University, 3rd floor William Leech Building, The
Medical School, Framlington Place, Newcastle upon Tyne NE2
4HH, UK
Semin Immunopathol
DOI 10.1007/s00281-017-0655-8
and lessons learnt from past and present clinical studies.
Innovative approaches that are emerging to overcome obsta-
cles blocking success will be explored, highlighting drugs in
development which employ these state-of-the-art strategies.
Complement activation and control
Complement is activated by various different mechanisms,
and all converge at the point of C3 cleavage but differ accord-
ing to the nature of activation. The classical pathway is trig-
gered by a ‘lethal array’ of antibody on a target surface, the
lectin pathway is initiated when a lectin such as mannan-
binding lectin (MBL) binds a pathogen, and the alternative
pathway constantly ‘ticks over’ in fluids, priming the system
to enable rapid response in the face of infection; this back-
ground turnover of complement results in continual surveil-
lance of tissues and preservation of health; there are many
excellent reviews in this area [1–4]. It is also clear that com-
plement links to adaptive immunity by engaging receptors on
immune cells, such as B cells, and supporting the generation
of an effective immune response. Opsonisation of antigens
with the complement fragment, C3dg, results in co-
engagement of the B cell receptor and complement receptor
2 (CR2; CD21) and synergistic downstream signalling, low-
ering the threshold concentration of antigen required to acti-
vate the cell [5, 6]. Multiple complement activation fragments
(C3a, C3b, C5a) bind respective receptors and influence Tcell
differentiation and maturation of antigen-presenting cells de-
pending on the surrounding cytokine milieu; these effects can
be very localised and driven by complement synthesised in
specific tissues [7].
Complement activates in an exponential way due to an
internal amplification loop [8]. The largest fragment of acti-
vated C3, C3b, produced due to the actions of any of the
activating pathways, can bind factor B (CFB) to form the
proenzyme C3bB. Binding of factor D (CFD) results in pro-
teolytic cleavage of CFB and formation of the C3 convertase,
C3bBb. This is a labile enzyme with a half-life of only mi-
nutes due to irreversible dissociation of components, but bind-
ing of properdin can stabilise and prolong activity for up to
half an hour. During its lifetime, the C3 convertase cleaves
many molecules of C3 to C3b, each with potential to form a
C3 convertase in its own right. This results in an amplifying
cycle right at the heart of the cascade which transforms a small
trigger to massive downstream effect (Fig. 1).
Unfortunately, this volatile and rapid-acting system can do
harm as well as good. In health, the system is constantly acti-
vating, but that is in perfect balance with control mechanisms
which allow sufficient flux through the pathway to recognise
appropriate (foreign) targets, but limit ‘tickover’ amplification
and activation on self-surfaces [3, 9]. There are various control
mechanisms which inhibit the cascade:
i) Inherent instability; examples include the short half-
lives of complexes such as C3bBb, and the limited time
for which nascent C3b can bind covalently to a target,
or that C5b can bind C6 to form C5b6.
ii) Decay accelerating activity; various proteins on cell
surfaces (CD55, CD46, CD35) and in fluids (comple-
ment factor H (CFH), C4b-binding protein) bind to the
C3 and C5 convertases and accelerate the labile decay
of the components resulting in virtually instantaneous
loss of the proteolytic subunits (such as Bb).
iii) Cofactor activity; this is inherent to CD46, CD35, CFH
and C4bp; binding to their ligand (C3b, C4b) enables a
soluble serine protease, factor I (CFI), to bind the com-
plex and proteolyse either component preventing fur-
ther proenzyme and convertase formation.
iv) Inhibition of the lytic pore, the membrane attack com-
plex (MAC); the widely expressed MAC inhibitor,
CD59, binds to the terminal proteins as they start to
form the MAC and prevents polymerisation of C9.
Other proteins present in the fluid phase, S-protein,
clusterin and even C8, bind to the activated MAC com-
ponents before they have a chance to associate with a
membrane and render the complex soluble.
Complement and disease
Variousmechanisms can disrupt this balance resulting in over-
activation, damage and disease (Fig. 2); there are already
many outstanding reviews in this area [10–15]; disease trig-
gers may be inherited or acquired and are only described in
brief here. Mutations in the complement genes translate to
proteins which can cause loss or gain of function. Loss of
function of an inhibitory protein, such as CFH which controls
the amplification loop, can result in over-activation of the
system and inflammation. Similarly gain-of-function changes
in activating proteins can cause imbalance, often impacting in
a similar way by weakening affinity of control proteins for
their ligand (binding of CFH to its major ligand, C3b, or to
self-surfaces where it restricts activation) [13]. Common
changes in complement proteins (polymorphisms) can also
impact function, although the effect on function is often slight
and only apparent when risk polymorphisms occur concur-
rently inmultiple proteins [16]. Expression levels of activating
components and regulators vary enormously in the healthy
population, but drastic losses in expression, due to a non-
sense mutation, for example, can upset the balance and cause
loss of control. This mechanism is evident in diseases such as
age-related macular degeneration (AMD) where low level ex-
pression of the enzyme CFI results in inefficient conversion of
C3b to the downstream fragment, iC3b [17]. Acquired drivers
of disease include autoantibodies, for example to the
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acetylcholine receptor in myasthenia gravis, which can drive
complement activation in an inappropriate manner.
Autoantibodies can bind to components and complexes and
alter function; for example, nephritic factors can stabilise the
C3 and C5 convertases and are associated with diseases such
as C3 glomerulopathy (C3G) and acquired partial
lipodystrophy (APL). Environmental triggers also play a role
and an example of this might be oxidation of lipids in the
retina of individuals at risk of AMD, or pregnancy in the case
of individuals at risk for atypical haemolytic uremic syndrome
(aHUS) [18].
The complement cascade is an excellent example of a bio-
logical pathway whose activation and progression is
characterised by an exquisite set of conformational transitions
[19–21]. A conformational change in one activating protein
reveals binding sites for the next in the cascade, which in turn
changes shape upon binding and facilitates engagement of the
following component. Early steps in the pathway are
characterised by proteolytic cleavage (for example, C3 to
C3b, CFB to Bb, C5 to C5b), whereas later stages of the
pathway simply involve conformational transitions subse-
quent to a binding interaction (C6 through to C9 and MAC
formation), Fig. 1. Given the plethora of diseases in which
complement is activated, the cascade presents an enticing
challenge for drug discovery with potential to inhibit en-
zymes, prevent protein/protein interactions and interfere with
conformational transitions.
The current drug development landscape
Complement drug discovery is not a new concept; recombi-
nant DNA technology has long been used to generate soluble
forms of complement control proteins to bolster circulating
levels of inhibitory proteins. These agents have had success
in animal models of disease, and have even made it in to man
(for example, TP10; soluble complement receptor 1, sCR1),
but have so far struggled to make it to, or to progress through,
clinical development [22, 23]. An exception is C1 inhibitor
(C1inh) which is used to treat hereditary angioedema (HAE);
HAE is triggered by a lack of C1inh which controls the
contact-system protease, kallikrein, as wells as the activating
complex of the classical pathway, C1; however, C1inh, either
recombinant (Ruconest) or native (Cinryze, Berinert), is used
to replace missing protein, rather than to block complement as
a therapeutic target [24]. Small molecule inhibitors of the
complement cascade have been sought for several decades
but often show off-target effects and toxicity in animals.
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Fig. 1 The complement amplification loop. Complement is activated by
various triggers including binding of lectins or antibody to a target surface
or by background ‘tickover’ of the alternative pathway. The pathways
converge at the point of C3 cleavage to C3b andC3a by the C3 convertase
(either C3bBb or C4b2a). The larger cleavage fragment, C3b, binds CFB
to form a proenzyme which is activated by CFD to form further
convertase, C3bBb. This enzyme cleaves many molecules of C3 to C3b
each of which is capable of amplifying the pathway as illustrated in the
cycle (in bold), or forming the C5 convertase, C3bBbC3b (grey), which
cleaves C5 to C5b and C5a and triggers the terminal pathway. This
feedback cycle amplifies the signal from any small trigger to a large
downstream effect. The proinflammatory by-products of complement
activation are the anaphlylactic and chemotactic peptides, C3a and C5a
and the membrane-associated macromolecular complex, MAC
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Only recently have various small molecule inhibitors of the
enzymes CFB and CFD been developed and translated to
man; these are currently undergoing early-stage clinical trials
[25, 26]. Antagonism of complement receptors by small mol-
ecules has also been tried and tested over many years with
limited progression to man. One such inhibitor of the C5a
receptor (C5aR1), termed avacopan or CCX168, is now
reaching the late stages of clinical development; it is ap-
proaching phase 3 studies for ANCA vasculitis [27].
Complement knockout animals have illustrated the poten-
tial for blockade of components for therapy in animal models;
similarly, blocking antibodies have shown promise, but limi-
tations around target concentration and local biosynthesis are
clearly evident in models and in man. Various strategies to
block or ‘knockout’ components in man have been tested in
the clinic, these include monoclonal antibodies against com-
plement components or nucleotide-based therapies (antisense,
RNAi) which primarily target the liver, the main (but not
only!) source of complement in man [28]. One agent, a
humanised monoclonal against C5, eculizumab, is the first-
in-class drug approved for two orphan diseases, paroxysmal
nocturnal hemoglobinuria (PNH) and aHUS [29, 30]. Various
other strategies have been tried and tested, with varying suc-
cess (Fig. 3).
The drug development landscape is littered with agents that
have failed at the preclinical or early clinical stage [30]. Their
modes of action and modalities are wide-ranging. It is
becoming increasingly clear that an understanding of disease
mechanism and matching of drug modality and mode of ac-
tion to the right disease and patient population (or stratified
subpopulation) is critical to success. There are some disease
indications where studies of genetics, biomarkers and tissues
illustrate a primary role for complement in pathogenesis (for
example, AMD, aHUS, C3G, PNH) and others where the
primary trigger is not complement but complement acts to
exacerbate downstream inflammation and tissue damage (for
example, rheumatoid arthritis, systemic lupus erythematosus).
A range of different drugs, or combination of drugs, will be
needed for effective management of the many and diverse
complement-mediated diseases. This figure is adapted from
Morgan BP, Harris CL. Nat Rev Drug Discov. 2015
Dec;14(12):857–77; ‘Complement, a target for therapy in in-
flammatory and degenerative diseases’ [30].
Challenges in anticomplement drug development
Disease mechanism
The reasons behind the low success rate for anticomplement
drugs are clear. An in depth understanding of disease mecha-
nism and the contribution of complement is critical to success
and that knowledge has not always been there. This under-
standing will include knowledge of the disease trigger(s) and
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Fig. 2 Complement activation and control and mechanisms of
dysregulation. The complement system is always activating at a
background ‘tickover’ level which enables rapid response in the face of
infection; activated C3b deposited on a non-self (or unprotected) surface
will fire the amplification loop. In order to prevent harm to self-tissues, an
armoury of complement regulatory or control proteins exists in plasma
and on self-cells to inactivate complement as it becomes activated, these
proteins include factor H (CFH), CD46, CD55 and CD59. In health, there
is sufficient flux through the system to drive activation on foreign cells,
whilst damage to self is prevented. If this perfect balance between acti-
vation and control is disturbed, then tissue damage and disease may
ensue. Various mechanisms tip the balance in favour of inflammation or
infection and those are illustrated here. These include mutations and
polymorphisms which affect function of the activating or control proteins,
expression levels of these proteins (which may in some cases be zero),
autoantibodies which drive complement in an inappropriate manner, and
environmental triggers
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its link(s) to the complement activation pathway(s) involved (lec-
tin, alternative, classical and terminal). Complement activation
fragments deposited in diseased tissue or circulating in blood at
elevated levels, indicate complement activation in pathology, but
do not necessarily pinpoint a primary role in disease, or distin-
guish cause from effect. Not only is knowledge of the causal
pathway extremely important to target the right therapy to a dis-
ease indication but homing in on just one arm of the system leaves
other pathways to function and preserve the infection-fighting and
life-preserving properties of complement. Examples of drugs in
clinical development which target a specific pathway include
TNT009 (True North Therapeutics; acquired by Bioverativ in
2017) which is a blocking antibody against C1s, an enzyme
specific to classical pathway. This is being tested in antibody-
driven diseases such as bullous pemphigoid and cold agglutinin
disease. Omeros is developing a monoclonal antibody
(OMS721) against the lectin pathway-specific enzyme, MASP-
2, for thrombotic miroangiopathy and various renal indications.
Perhaps the best known agent is eculizumab, an antibody against
C5 which selectively inhibits C5 activation and MAC formation
and leaves the activation pathways and therefore the pathogen-
opsonising functions of complement unaffected [29].
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Fig. 3 The current complement drug development landscape. This
schematic illustrates drug which are being developed for clinical use,
either approved (bullseye, yellow) or in the pipeline (remainder of
target; clinical trial, black-red; preclinical, white). Complement drug
discovery is a rapidly moving field and, inevitably, some compounds
will progress, others will fail and new drugs will emerge to take their
positions in the landscape in the coming years. Antibodies (whole Ig or
fragments) in development or approved include eculizumab (Alexion), a
blockbuster drug approved for treatment of PNH and aHUS, and its
follow-up molecule ‘next-generation eculizumab’ ALXN1210 (phase
3). Lampalizumab (Genentech/Roche) is in phase 3 for geographic atro-
phy, IFX-1 (InflaRx) is an anti-neo C5a, and LFG316 and CLG561 are
specific for C5 and properdin (both developed by Novartis). Other anti-
bodies which are pathway-specific include OMS721 and OMS906
(Omeros) against lectin pathway proteins, TNT009 (True North therapeu-
tics) specific for C1s, PRO-02 (Prothix) against C2, and ANX005
(Annexon Biosciences) against C1q. Novelmed have antibodies against
CFB (bikaciomab) and properdin (NM9401) in preclinical development.
Other antibodies block C5 or MAC and include SKY59 (Chugai/
Roche)—a sweeping antibody against C5, ALXN5500 (Alexion) specific
for C5, Regenemab—an antibody specific for C6 (Regenesance) and
Mubodina (Adienne Pharma & Biotech), an antibody against C5 being
developed for typical HUS. Cinryze, Berinert and Ruconest are all C1
inhibitor, either native (Cinryze, Berinert) or recombinant (Ruconest)—
approved for HAE. Various other biologics target the alternative pathway
including TT30 (Alexion), Mirococept (King’s College London/MRC)
and AMY-201 (Amyndas). SOBI-005 (SOBI) is an affibody and
Coversin is a recombinant tick protein, both biologics which block C5.
Peptide-based agents include the alternative pathway blockers, all derived
from Compstatin: AMY-101 (Amyndas), APL-1 and APL-2 (both
Apellis Pharmaceuticals), and the C5-blocking peptide from RaPharma,
RA101495. Small molecules which target complement have been slow to
develop but success is now evident with CCX-168 (ChemoCentryx; C5a-
receptor blocker) and ACH-4471 (CFD blocker, Achillion
Pharmaceuticals); trials of the SM inhibitors of both CFD and CFB
(Novartis) are anticipated. Small molecule inhibitors of properdin
(Novelmed) have been described although recent development is not
reported. There are a small number of nucleic acid-based therapies which
have been developed which bind target and block function, these include
Zimura (Ophthotech), an aptamer which blocks C5, NOX-D19-D21
which bind C5a (Noxxon Pharmaceuticals) and DF-2593A (Dompé)
which binds C5a receptor and blocks via an allosteric mechanism.
Finally, various agents which function at the gene expression level are
under development and these include antisense for CFB (IONIS-FB-
LRx; Ionis Pharmaceuticals), RNAi for C5 (ALN-CC5, Alnylam
Pharmaceuticals), and an agent under development by Regenesance
based on locked nucleic acid (LNA) technology, which prevents C6 ex-
pression. This figure is adapted from Morgan BP, Harris CL. Nat Rev.
Drug Discov. 2015 Dec;14(12):857-77; ‘Complement, a target for thera-
py in inflammatory and degenerative diseases’ [30]
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Knowledge of disease mechanism is built using a variety of
data. Animal models can provide powerful insight, although care
must be taken when extrapolating results to man [31]. Genome-
wide association studies (GWAS) and candidate gene studies
have provided powerful data over the last decade, shedding light
on complement associations with common and devastating dis-
eases such as AMD and Alzheimer’s disease (AD) [15, 32].
Genetic association of multiple proteins within a biological path-
way have been particularly enlightening. Association of multiple
proteins in the amplification loop, both activating and controlling
proteins, with AMD provide powerful evidence for this pathway
as a primarymediator of pathology [16]. Proteins associated with
risk include the activating proteins C3 and CFB and the control
proteins CFH, CFI and the CFH-related proteins (CFHRs); in-
deed, intravitreal inhibition of the amplification loop with an
inhibitor of CFD (lamaplizumab) is a strategy which showed
promise in phase 2 studies of geographic atrophy and is currently
being tested in phase 3 trials [33]. Development of this agent was
likely driven by the genetic studies which highlighted the ampli-
fication loop as a primary target in this disease. Common poly-
morphisms alter risk for disease, but alone, do not cause disease.
Advances in genetic screeningmean that strategies such aswhole
exome sequencing and multiplex ligation-dependent probe am-
plification (MLPA) are affordable and rapid and are now com-
monly used to identify mutations and genetic changes in individ-
ual patients which are highly penetrant and are disease-causal on
their own.Very often, these genetic analyses are used in the clinic
for diagnosis, but ability in this current era to move from patient
phenotype, to causal gene and then to functional dissection of
pathogenic mechanism in the research environment is incredibly
powerful and provides unprecedented insight into disease mech-
anisms [13].
Matching the drug to mechanism is one key to success.
Stratifying within a patient population might also be impor-
tant. For example, C3G is a disease caused by dysregulation of
the amplification loop which causes renal failure. Therapy
with the anti-C5 mAb eculizumab has been hit and miss, with
some patients showing improvement and others none. It is
becoming increasingly clear that some individuals within that
patient population show distinct dysregulation at the level of
the C5 convertase which may be a driver to an acute inflam-
matory phenotype within the kidney; it is entirely possible that
these patients, and these alone, might benefit from anti-C5
therapy [34, 35]. In the UK, the National Health Service
England (NHSE) has approved use of eculizumab only for
those patients who have confirmed activation of C5 and de-
position of MAC within a transplanted kidney [36].
Stratification of patient populations is probably critical for
successful outcome of clinical trials and goes beyond C3G
to include disease indications such as myasthenia gravis (pos-
itivity for complement-activating anti-ACHR antibodies) and
AMD (presence of a risk genetic makeup or ‘complotype’). In
the MAHALO phase 2 trial (Genentech) in geographic
atrophy, the CFD inhibitor, lampalizumab, slowed disease
progression most prominently in individuals with a particular
genetic makeup which notably linked to a polymorphism in
the CFI gene [33]. It is noteworthy that a recent press release
fromGenentech (September 8, 2017) reported that the phase 3
study (SPECTRI) did not meet its primary endpoint of reduc-
ing mean change in geographic atrophy lesion area; it is not
yet clear whether genetic analyses have been performed.
Side effects of therapy
Beyond identifying disease mechanism, there are clear hurdles
to overcome in the drug development process, including side
effects of inhibiting the complement system, such as risk of
infection [2, 37]. An inability to formMAC is associated with
increased risk of infection with the Gram-negative bacterium
Neisseria meningitides, as illustrated in individuals with ge-
netic deficiency of a terminal pathway protein such as C6.
Deficiency of a protein earlier in the cascade, such as C3,
CFB or CFD is associated with a wider range of infections
as ability to opsonise with (i)C3b is also impacted. The num-
ber of families harbouring a (homozygous) genetic defect in
these proteins are limited, but studies indicate that individuals
suffer from recurrent bacterial infections with diverse organ-
isms, including of the genera Neisseria meningitidis,
Enterobacter aerogenes , Haemophilus influenzae ,
Escherichia coli, group A streptococcus, Streptococcus
pneumoniae, Streptococcus pyogenes and Staphylococcus
aureus [38]. There are a number of strategies employed to
mitigate these infection risks, these include prophylactic anti-
biotics and vaccination. Vaccination against Neisseria
meningitides is a prerequisite prior to administering
eculizumab, whereas multiple vaccinations may be required
to overcome risk encountered by inhibiting the amplification
loop. Apellis Pharmaceuticals are in early clinical trials in
PNH of an agent, APL-2, developed from the C3 inhibitory
peptide, compstatin [39]. Trial inclusion criteria include doc-
umented evidence of administering Neisseria meningitides
vaccine, Pneumococcal conjugate vaccine (multivalent) or
Pneumococcal polysaccharide vaccine 23 (PCV13 or
PPSV23) and Haemophilus influenzae Type B (Hib) vaccine
(www.clinicaltrials.gov; NCT02588833). Various forms of
compstatin (APL-2, AMY-101 (Amyndas)) are currently in
the clinic with agent being administered systemically; the
presence or absence of adverse events in these trials will be
incredibly informative to the drug discovery field.
Intriguingly, an interim report on the Apellis phase 1b studies
(NCT02588833, NCT02264639) was recently released by the
company (press release, June 29th 2017). It indicated that
there were no significant drug-related safety concerns over
the 6-month systemic treatment with APL2, further data are
anticipated.
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Achillion Pharmaceuticals and Novartis are both
progressing small molecule inhibitors of CFB and CFD and
are pioneering studies of relative infection risk due to inhibi-
tion at either the C5 level or within the amplification loop.
In vitro studies using whole blood have been reported and
indicate a greater negative impact on bacterial clearance from
C5 inhibition as opposed to CFB/CFD [40]. In these assays,
the chemotactic/anaphylactic peptide, C5a, is clearly required
for effective activation of leukocytes in order to engulf path-
ogens. When the amplification loop is inhibited, the classical
and lectin pathways in an adult may be sufficient to provide
adequate C5a for cell recruitment and activation. It remains to
be seen whether the augmentative effects on adaptive immu-
nity of the C3 and C5 activation fragments are impacted fol-
lowing long-term administration of these inhibitors. It could
be speculated that blockade of C3 and C5 may impact the
efficiency of vaccination, particularly with respect to activa-
tion of memory cells [7].
Complement also has key roles in tissue homeostasis and
preserves health by facilitating removal of immune complexes,
apoptotic cells and debris; thus, interfering with these clearance
mechanisms could pose a risk to health. As an example, indi-
viduals with a genetic defect in the classical pathway have high
risk of developing lupus-like symptoms; 93% of individuals
lacking C1q and 57% lacking C1r/s present with a lupus-like
illness [41]. It is not known whether risk will be similar in
individuals who acquire deficiency later in life due to therapeu-
tic inhibition, but current clinical trials, such as that run by True
North Therapeutics (phase 1, NCT02502903; anti-C1s anti-
body), may shed light on this issue. Participants are vaccinated
against Neisseria meningitidis, Haemophilus influenzae and
Streptococcus pneumoniae to mitigate infection risk, and clin-
ical biomarkers will inform on the safety profile.
Infection risk can also be mitigated by selective targeting of
the complement pathway. Although a defect may be present in
activation pathways, if the pathogenic mediator is down-
stream, then the drug target does not necessarily need to be
within the defective pathway. Examples of this are PNH and
aHUS. In both diseases, blockade of C5 with eculizumab re-
sults in profound clinic benefit, yet in both indications there is
a clear defect in the activation pathways. Eculizumab prevents
the proinflammatory impacts of C5a and MAC evident in
aHUS, and prevents the MAC from lysing and activating cells
in PNH; thus, blockade at the level of C5 can relieve symp-
toms [42]. In both these treatment regimes, vaccination is only
required against those pathogens that are directly lysed by
MAC (Neisseria meningitidis). By inhibiting downstream of
the defective pathway, the opsonising properties of the activa-
tion pathways and amplification loop are preserved. However,
there may be drawbacks to this strategy and this is evident in
the eculizumab-treated PNH population. A large number of
patients are rescued from transfusion-dependent status due to
anti-C5 therapy, but it is becoming increasingly clear that
therapy triggers a secondary clinical complication in PNH
[43]. Defective erythrocytes in untreated individuals normally
lyse due to MAC formation, but when MAC is blocked these
cells become highly decorated in fragments of activated C3
due to lack of the GPI-anchored inhibitor of the amplification
loop, CD55. A subset of individuals remain transfusion-
dependent due to extravascular (rather than intra-vascular)
hemolysis of these C3 fragment-labelled cells. If a drug does
not rectify the original disease-triggering problem, it is clearly
important to monitor any magnified secondary pathology due
to that ongoing causative defect.
Target concentration and turnover
Risk to health posed by therapeutic inhibition of complement
is one challenge facing complement drug discovery and de-
velopment. Another obstacle in complement drug discovery is
target concentration. Unlike most cytokines which are present
(transiently) in plasma at just picograms per millilitre, com-
plement proteins are present at huge amounts; between 3 and
5% of total plasma protein are complement proteins!
Complement proteins are released by the liver and also at
many extrahepatic sites [28]; in inflammatory disease, local
biosynthesis can contribute significantly to complement in
that environment. Target concentration and turnover both im-
pact on drug dose—it is understandable why eculizumab has
to be administered intravenously at 1200mg every other week
to patients being treated for aHUS as levels of the target, C5,
are high at between 90 and 172 mg/litre in the healthy popu-
lation (0.44 μM average concentration; reference ranges ac-
cording to Cardiff and Vale University Health Board
Immunology Reference Laboratory; ht tp: / /www.
cardiffandvaleuhb.wales.nhs.uk/immunology); even at high
doses, breakthrough can occur [44]. Requirement for high
dose of antibody not only costs more but also limits ability
to administer drugs via a subcutaneous route, which would be
ideal for long-term therapy; a single subcutaneous injection is
limited to 1–2 ml volume of antibody at between 100 and
150 mg/ml (approximately 2–3 mg/kg in human).
Additional problems may be encountered when an individual
is ill, as most complement proteins are acute phase reactants
and thus levels can increase and breakthrough symptoms may
occur due to insufficient blockade. There are some comple-
ment proteins which are synthesised only at extrahepatic sites,
such as C1q, C7 and properdin, and these may therefore pres-
ent as better targets. However, levels are not necessarily low
(C7 normal range is 55–85 mg/litre) and local biosynthesis at
sites of inflammation and disease, rather than systemic levels,
may have profound effect on pathogenesis.
The impact of turnover on drug dose is illustrated by agents
which target the amplification loop protein, CFD. CFD is a
small protein subjected to high renal filtration; it is reported
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that CFD turnover might be as high as 1.33 mg/kg/day [45,
46]. In vivo studies in cynomolgus monkeys with
lampalizumab, a humanised Fab which binds the CFD exosite
with picomolar affinity, indicated that the pharmacokinetic/
pharmacodynamic (PK/PD) properties of this agent were
unfavourable when administered systemically [47]. High
doses were required to block the amplification loop and con-
centration of CFD increased tenfold in plasma due to
antibody-mediated antigen accumulation. This agent is given
locally into the eye in humans and is in phase 3 for geographic
atrophy; however, intravitreal therapy clearly has limitations
for a large patient population, particularly if early-stage (pre-
blinding) disease is to be targeted and development of late-
stage disease prevented. It remains to be seen whether system-
ic inhibition of the complement system has any impact on
progression of AMD. Another asset which inhibits CFD,
ACH-4471 (Achillion Pharmaceuticals), can be given via oral
dosing—an exciting breakthrough for the field. Interim data
from the phase 1 study indicated that the dosing was high, and
administration was required several times a day to totally sup-
press the amplification loop [48]. Nonetheless, the data indi-
cate that oral medication can suppress the complement sys-
tem. It remains to be seen how this agent, and others like it,
will fare in a disease state.
Whilst it is clear that delivery issues are a major impedi-
ment to effective anticomplement therapy, the field has ad-
vanced rapidly in the last decade with a plethora of clinical
studies progressing; we are in a place where hard evidence
from failed and successful studies in man has already, or will
in the near future, back up or refute concerns around dosing or
side effects. Data from clinical studies have galvanised and
guided drug development and we see a new generation of
enhanced drugs emerging in the clinic; for example, next-
generation eculizumab (ALXN1210) is a version of the orig-
inal drug engineered to enhance its PK properties (see below).
It is in phase 3 studies and clinical data demonstrate that this
anti-C5 antibody can be dosed every other month, rather than
every other week. Innovative strategies such as those de-
scribed below to decrease dose and enhance effective delivery
are emerging and will dominate the complement drug land-
scape in the next decade.
Engineered antibody strategies to reduce dose
Various approached have been developed to modulate drug
dose, including engineering of either, or both, the Fc and
Fab domains of antibodies. Recycling, or ‘pH switched’, an-
tibodies have been developed to reduce dose [49, 50].
Antibody-based therapeutics usually bind target with high af-
finity and circulate as a complex until cleared. Typically, the
complex is internalised into the endosome compartment of
cells where the Fc of the drug binds to FcRn in the slightly
acidic environment (pH 6). Binding to FcRn ‘rescues’ the
antibody as it is recycled to the cell surface where it is released
due to the neutral pH of blood (pH 7.4), at this pH the affinity
for Fc and FcRn is lowered. If antigen or target-binding to the
antibody idiotype is not impacted at pH 6, then the target
recycles along with antibody and the complex is released back
to the bloodstream, a process which can result in accumulation
of target in blood, sometimes as much as 1000-fold [50, 51].
Recycling antibodies are engineered to take advantage of the
acidic environment of the endosome. The antigen-binding do-
main is modified, often by substituting histidine residues into
the CDRs, this introduces pH-dependent binding and weakens
affinity for antigen at pH 6 such that the antigen is released in
the endosome following internalisation. Endosome/lysosome
fusion results in degradation of the soluble antigen and
recycling of the antibody bound to FcRn via the sorting endo-
some back to the cell surface. This releases antibody back to
the circulation that is free to bind target once more, hence drug
dose is reduced. The first therapeutic antibody to be pH
switched was tocilizumab (anti-IL6 receptor), reported in
2010 [49]; however, this strategy has since been employed
to generate long-lived anticomplement antibodies. The
‘next-generation eculizumab’ antibody, ALXN1210, is an
engineered form of eculizumab which has marginal reduction
in affinity for C5 at pH 7.4, but marked reduction at pH 6 [52].
ALXN1210 is currently administered intravenously every
other month for patients with PNH (clinical trial identifiers:
NCT02946463, NCT03056040). In this case, the recycling
technology was applied to an existing agent, and there are a
number of other published examples of histidine-based engi-
neering of antibody CDRs; however, this approach poses the
risk of impacting binding to target at neutral pH in the circu-
lation. Others have set out to identify antibodies with high
potential for pH switching during the drug screening process.
Chugai Pharmaceuticals generated monoclonal antibodies
from C5-immunised rabbits and screened for those with lower
binding affinity at pH 5.8 compared to pH 7.4 and identified a
clone with undetectable binding at pH 5.8 and nanomolar
affinity (KD) at pH 7.4. This antibody was humanised and
further mutations introduced to the variable region to improve
affinity, resulting in an antibody (SKY59/RG6107; collabora-
tion with Roche) with subnanomolar affinity (KD 0.152 nM)
and a 1000-fold lower binding affinity for C5 at pH 5.8 [53].
Exquisitely designed in vitro studies utilising MDCK (Madin-
Darby Canine Kidney Cells) cells expressing FcRn-EGFP and
incubated with Alexa 555-labelled C5 and either SKY59 or a
control antibody provided compelling evidence for release of
C5 from SKY59 within the endosome. The target, C5, could
be seen to accumulate within the endosomal space, whereas C5
bound to the control antibody (which did not demonstrate pH
dependence of binding) colocalised with FcRn at the
membrane (Fig. 4). Crystal structures revealed the epitope
of SKY59 on C5 which differs from that of eculizumab and is
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distal to a polymorphism in C5, R885H, which precludes
eculizumab binding to target. In vivo studies in mice and cyno-
molgus monkeys validate the positive effect of recycling tech-
nology on drug PK and clearance of C5; in addition C5 did not
accumulate in plasma of monkeys treated with SKY59 [53].
Clinical experience with ALXN1210 validates this antibody en-
gineering approach and we await data from the current phase 1/2
clinical trial of SKY59 in PNH which also utilises subcutaneous
injection route rather than intravenous infusion.
Other strategies are used to improve performance of antibody-
based drugs such as affinity maturation or mutation within the
CDRs to improve affinity for target. Unless complement-
dependent cytotoxicity (CDC) or antibody-dependent cellular cy-
totoxicity (ADCC) are desired modes of action, antibodies which
bind cell surface targets are usually modified to eliminate binding
of the first complement component, C1q, and to Fcγ receptors
(FcγR). These modifications typically involve switching to the
IgG4 isotype which lacks these binding interactions, or point
mutations within the Fc domain of heavy chain of an IgG1 anti-
body [54]. However, other Fc engineering strategies can improve
therapeutic potency of antibodies, such as mutating the binding
site for FcRn to increase the slow rate of non-specific uptake into
cells. If this strategy is applied to a pH-dependent antibody, it
results in a ‘sweeping’ antibody with enhanced capacity to bind
to FcRn at the cell surface and deliver target to lysosome for
degradation whilst recycling the antibody to the surface of the
cell [55, 56]. A sweeping antibody can bind FcRn at neutral pH
on the cell surface, resulting in accelerated uptake and degrada-
tion of larger amounts of soluble antigen compared to that
achieved with an antibody with recycling properties alone; for
sweeping technology to work, pH dependence to release antigen
in the endosome is essential [55]. The affinity of antibody for
FcRn at neutral pH can impact its rate of clearance; therefore, the
balance between accelerated target clearance due to the sweeping
action and enhanced antibody clearance must be taken into con-
sideration when considering the engineering strategy. A moder-
ate increase in FcRn affinity may be sufficient to enhance drug
potency without impacting clearance [55].
One further strategy for improving antibody PK is emerging
but not yet tested in humans. FcyRIIb plays a key role in uptake of
immune complexes in the liver and possibly represents a ‘more
natural’ route for antigen removal than via the widely expressed
FcRn. It is not known whether systemic clearance via FcRn is
preferable to liver-mediated clearance via FcyRIIb, but in vivo
studies in transgenic mice indicate that engineering the binding
site for this receptor in combinationwith pH switching accelerated
clearance of soluble antigen from the circulation [57].
Targeting neoepitopes at sites of disease
Most complement proteins are present in plasma at high
levels; properdin (2 μg/ml), CFD (25 μg/ml) and MASP2
(300 ng/ml) have lower circulating concentrations which
may simplify drug delivery, but drug dose may be impacted
by turnover; this is certainly the case for CFD. Most
complement proteins have a normal concentration which is at
least approaching 0.1 g/L and many are much higher (CFB,
normal range (n.r.) 0.295–0.4 g/L; C3 n.r. 0.75–1.65 g/L; C4
n.r. 0.14–0.54 g/L; C5 n.r. 0.09–0.172 g/L; C9 n.r. 0.05–0.25 g/
Fig. 4 Mode of action of ‘sweeping’ antibodies. Antibodies designed to
bind well to antigen and FcRn at pH 7.4 (blood) but to lose binding to
antigen at pH 6 can demonstrate a ‘sweeping’ action. This figure, taken
from Fukuzawa et al. Sci Rep. 2017 Apr 24;7(1):1080, contrasts the
mechanism of C5-binding and C5-release by two monoclonal antibodies:
SKY59, a sweeping antibody against C5, and CFA0322, a non-sweeping
antibody against C5. These images demonstrate representative images of
human C5 localization in endosomal vesicles. MDCK cells expressing
human FcRn-EGFP were treated with Alexa 555-labelled C5 and either
SKY59 (d–f) or CFA0322 (g–i). Red and green represent C5 and FcRn,
respectively. C5 was released into the endosomal space in cells treated
with SKY59 whilst C5 remained bound on the endosomal membrane in
cells treated with (control) CFA0322. Scale bars represent 2 μm. The
experiments were repeated twice for representative images. This figure
is adapted from the following publication: Fukuzawa T, Sampei Z,
Haraya K, Ruike Y, Shida-Kawazoe M, Shimizu Y, et al. (2017). ‘Long
lasting neutralization of C5 by SKY59, a novel recycling antibody, is a
potential therapy for complement-mediated diseases’. Sci Rep 7:1080.
https://doi.org/10.1038/s41598-41017-01087-41597; the original article
can be accessed at this URI http://www.nature.com/articles/s41598-017-
01087-7 [53]. It is licensed under a Creative Commons Attribution 4.0
International License https://creativecommons.org/licenses/by/4.0/
legalcode [53]
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L; ranges currently cited by Cardiff and Vale University Health
Board ImmunologyReference Laboratory). These target concen-
trations necessitate huge amounts of drug such as that evidenced
by eculizumab (anti-C5) described above. Various strategies exist
to lower dose and enable subcutaneous administration, including
antibody engineering strategies described above, but another ap-
proach is to target neoepitopes on complement proteins which
appear as the proteins become activated and change conforma-
tion. Rather than saturating the system with sufficient drug to
take out an entire component of the system, it is possible to
develop agents which bind to freshly exposed faces only present
on the activated proteins. These agents may be antibodies, and
there are abundant reagents with similar binding properties de-
veloped for techniques such as immunoassay-based detection of
activation products in plasma, or immunohistochemical detection
of activated complement deposited in tissues, or they may be
proteins which bind activated complement as part of their natural
function, such as complement receptors or complement control
proteins.
Antibodies against neoepitopes on complement proteins
Various antibody-based strategies have been developed for
targeting complement neoepitopes and several agents are
progressing through clinical development. IFX-1 (CaCP29)
is a humanised anti-neo antibody which targets C5a but has
no impact on MAC formation. Unlike the many other agents
currently under development which target at the level of C5,
IFX-1 does not bind the native C5 protein but only the acti-
vated C5a product; by binding C5a, it prevents engagement of
receptors on leukocytes such as neutrophils and T cells and
thus prevents the inflammatory cellular response. The agent
binds C5a generated via the complement C5 convertase and
other enzymes, such as trypsin and thrombin, thus has poten-
tial in disease indications, such as aHUS, where C5a may be
produced via multiple mechanisms [58]. It is in an advanced
stage of clinical development with various phase 2 trials
ongoing or completed. The SCIENS phase 2 trial (‘Studying
Complement Inhibition in Early, Newly Developing Septic
Organ Dysfunction’; NCT02246595) enrolled patients with
early organ dysfunction (within 3.5 h of screening); IFX-1
effectively blocked C5a in a dose-dependent manner and
showed positive trends in other endpoints such as organ
dysfunction score, need for ventilator support and length of
stay in intensive care. A phase 2 trial in cardiac surgery was
designed to evaluate whether prophylactic treatment with
IFX-1 could block the systemic (sterile) inflammatory
response often seen following major surgery, particularly
the severe and acute systemic inflammation and subsequent
organ dysfunction evident following cardiac surgery. The trial
(CARDIAC; ‘Studying Complement Inhibition in Complex
Cardiac Surgery’; NCT02866825) has completed. A third phase
2 trial in moderate to severe Hidradenitis Suppurativa (HS) has
been ongoing (2017; NCT03001622); HS is a common and
painful, long-term skin condition that causes abscesses and scar-
ring on the skin. Patients received weekly dosing of IFX-1 for
8 weeks with an expected impact on both neutrophil and T cell
function. At the time of writing, data are awaited from these two
clinical trials. This agent represents a significant advance in the
field as a therapeutic approach with potential to treat both acute
and chronic inflammatory disease.
Other drugs which target neoepitopes include a humanised
monoclonal antibody, H17 (Elusys Therapeutics), which spe-
cifically binds activated C3b and the downstream fragment,
iC3b, and blocks the amplification loop [59]. This agent has
potential for clinical application in alternative pathway-
mediated disease, such as C3G [60]. Genentech employed
phage display technology to generate an antibody, S77, which
bound C3b but not native C3 [61]. Structural studies of S77
and H17 in complex with C3b indicate that both agents bind
C3b within the macroglobulin 6 (MG6)-MG7 region and ste-
rically block interaction with CFB. The central complement
component, C3, turns over at a high rate in plasma due to
tickover and it is not yet clear how this impacts dosing of such
agents; recent clinical development is not reported for either
agent.
Several other agents have been reported with preferential
binding to activated complement, but as yet little data are
available. An anti-neo antibody specific for activated C1s,
TNT020, is reported in early-stage development by True
North Therapeutics. This agent follows in the wake of
TNT009, a monoclonal antibody which is in clinical develop-
ment for various complement-mediated disorders including
bullous pemphigoid (BP) and cold agglutinin disease.
Targeted delivery to neoepitopes
An alternative strategy to anti-neo antibodies is to ‘home’
agents to sites of complement attack using engineered
fragments of proteins or antibodies with affinity only to acti-
vated complement—this includes binding domains of
complement receptors and regulators with activities as de-
scribed above. One agent, TT30, is a chimeric molecule
comprising the iC3b/C3dg-binding domain of complement
receptor 2 (CR2, CD21) and the functional domains of CFH,
the resultant molecule ‘homes’ to sites of complement
activation via the CR2 domain and delivers therapy due to
decay accelerating and cofactor activities residing within the
CFH moiety [62]. This agent demonstrated marked therapeu-
tic benefit in various animal models and was initially
developed by Taligen Therapeutics, later being acquired by
Alexion Pharmaceuticals and tested in man in PNH (phase
1) [63]. The agent was administered by single-dose
intravenous infusion or separately by subcutaneous injection;
there were no dose-related safety risks and a transient
pharmacologically relevant inhibition of complement was
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evident in patients at the higher doses. Further development of
this agent has not yet been reported. One other Bhoming^ agent
to make it to clinical development is Mirococept (APT070).
This agent comprises functional domains from CR1 tagged to
a lipid ‘tail’ which facilitates binding to membranes [64]. It is
currently in phase 2 trial for delayed graft function (Mirococept
(APT070) for preventing ischaemia reperfusion injury in the
kidney allograft; EMPIRIKAL); the cytotopic property of
Mirococept endowed by the lipid tail enables an innovative
ex vivo delivery strategy whereby the agent is localised within
the microvasculature of the donated organ by perfusion prior to
transplant. This approach limits systemic effects whilst
maximising localised inhibition of complement. The trial
should read out towards the end of 2017 [65].
Other agents in preclinical phase of development include
‘mini-fH’, an engineered form of CFH comprising the amino-
terminal functional domains, which have decay accelerating
and cofactor activity, fused to the carboxy-terminal domain,
the resulting molecule binds avidly to self-surfaces undergo-
ing complement attack [66]. Various forms of this engineered
‘mini’ form of CFH have been tested in vitro and in animal
models and appear to be more effective on a molar basis than
the native CFH at protecting self-surfaces; one form of mini-
fH, AMY-201, is in preclinical development by Amyndas
Pharmaceuticals [67]. These agents all deliver inhibition of
the activation pathways of complement; however, one agent
has been developed which inhibits at the terminal stage and
prevents MAC formation; this has been tested in mice. In this
study, the iC3b-binding domain of complement receptor of the
Ig superfamily (CRIg) was fused to the MAC-inhibiting do-
main of the MAC inhibitor, CD59; the molecule was
dimerised by using recombinant DNA technology to insert
the hinge region of murine IgG2a (generating CD59-2a-
CRIg) and was shown to bind avidly to surfaces attacked by
complement [68]. CRIg binds to the C3c domain of activated
C3 and thus binds iC3b, but not C3dg; homing to iC3b should
focus the molecule to freshly activated complement, rather
than ‘old’ hot spots of complement activation which are likely
decorated in the end-stage degradation fragment, C3dg, rather
than iC3b [69]. This agent was administered systemically
(intravenously) 30 min post-injury in a murine model of trau-
matic brain injury (TBI) and successfully localised to the dam-
aged tissue. It decreased clinical severity score and prevented
MAC formation, axonal damage, cell stress and microglial
activation. These data illustrate the therapeutic potential of
homing agents but there are unanswered questions which
should be addressed for further optimisation of such mole-
cules in man. What is the appropriate homing target in
man—a species that lacks the widespread rodent complement
regulator Crry (complement receptor 1-related protein/gene y)
which supports cleavage of iC3b to C3dg? The cofactor en-
abling factor I to produce C3dg from iC3b in man (CR1) has a
limited distribution—does this mean that the blood and tissue
distribution of iC3b and C3dg differ across species? What
impact does the fluid phase tickover of the alternative pathway
have on dose—is there a massive fluid phase sump of C3
fragments that must be overcome to home effectively? Can
these agents provide therapy in diseases which have an ele-
ment of fluid phase dysregulation? Likely the answers to these
questions will differ according to the disease indication and
pathogenic mechanism but will need to be addressed to ad-
vance the field to clinical development.
One approach which may circumvent this issue is to home
therapeutic molecules to non-complement antigens which ap-
pear on diseased or damaged tissue [70]. One strategy that has
shown promise in preclinical models is to deliver to antigens
exposed due to tissue trauma or stress. These damage-
associated molecular patterns (DAMPs) usually trigger an in-
nate immune response and are associated with damage
resulting from a number of autoimmune and inflammatory
diseases and injury arising from conditions such as ische-
mia-reperfusion. These antigens include ligands which are
present on early and late apoptotic/necrotic cells and are
bound by natural antibodies whose role is to ‘sense’ danger.
A number of monoclonal antibodies have been generated
which recognise these antigens on stressed cells in mice and
they demonstrate specificity for modified annexin-4 (ANX4)
and modified phospholipids [71]. A scFv developed from the
anti-ANX4 antibody has been further developed as a chimeric
agent with a complement inhibitor and has shown to home to
the relevant site and protect against post-transplantation cardi-
ac reperfusion injury [72]. The possibility for translational to
man is supported by the presence of anti-ANX4 antibodies in
the plasma of a number of normal humans; in general, stress-
related antigens conserve well across species.
Activated complement products are at higher concentration
at sites of disease, with activation fragments often covalently
tagged to the cell surface. Generation of therapeutic agents
which specifically target or deliver to the surface-associated
antigens not only circumvents the challenge of dosing for a
high target concentration but also opens up the possibility of
localised, site-targeted therapy. The ideal ‘homing’ or
‘targeting’ agent should be capable of being administered sys-
temically, it should home to target specifically at disease site
without encountering any depot of ligand on the way, and
once delivered it should be retained at disease site to provide
lasting therapy. The complement-regulating moiety should
have a ‘recycling’ activity whereby it engages with a specific
conformation of target (for example, activated convertase,
C3bBb) to mediate a change such as decay of a complex, or
irreversible structural modification (such as cleavage by CFI).
It should then release and rebind to fresh active target, thus
preserving its ability to control complement at that site. The
exception to this might be when limited short-term therapy is
all that is required, such as that provided in TBI by the CD59-
2a-CRIg agent described above. This strategy of localised
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delivery has the distinct advantage of minimising systemic
inhibition and long-term risk of infection. It is logical that
homing agents should have these properties, but there are a
number of unknowns to be explored such as the affinity of the
homing arm for target—is it preferable to deliver an agent
with high avidity for binding the target or with low affinity
and ability to release and rebind rapidly at the surface? The
possibility of addressing this question is opened up by avail-
ability of monomeric and multimeric forms of homing agents
and also by use of recombinant antibody for delivery, not only
can antibody-based agents bind with multiple arms but also
mutation within the CDRs can generate agents with lower or
higher specificity for target antigen enabling in vivo experi-
mentation to answer this question.
Structure-based design for orally bioavailable
molecules
Intricate structural information is now abundant in the com-
plement field; this has not only provided critical insight into
the mechanism of action of existing drugs such as the C3
inhibitor, AMY-101 (compstatin derivative) [39, 73], but it
has also facilitated structure-based design of new drugs.
Various small molecules (SM) which are orally bioavailable
are now under development for use in man to inhibit comple-
ment; this delivery strategy represents an exciting leap for-
ward for the anticomplement field and has been enabled due
to the availability of high resolution crystal structures for in-
dividual complement proteins, such as CFB and CFD, and
complement complexes, such as the trimolecular complex of
C3b, CFB and CFD [20]. Oral bioavailability may circumvent
current issues with drug delivery. Both Achillion
Pharmaceuticals and Novartis have developed SM inhibitors
of CFD. The Novartis molecule was developed using a two-
pronged methodology combining structure-based design with
fragment-based screening [26]. Identification of potential
moieties that could dock into the CFD active site was steered
by prior knowledge of fragment binding to the related serine
protease, kallikrein-7. This ‘target-hopping’ approach guided
in silico docking of compounds to the crystal structure of CFD
and identified those molecules suitable for synthesis and sub-
sequent testing for CFD inhibitory activity in vitro. Aweakly
inhibiting compound was identified which was shown to bind
to CFD using [1 H, 15 N]-HSQC NMR spectroscopy. Further
in silico screening of a fragment (< 300 Da) library identified a
set of fragments docking into the active site of CFD and one of
these was shown to interact in vitro using ligand-observation
NMR. Guided by the molecular structure of both these hits, a
small molecule was designed and optimised with improved
affinity and selectivity and inhibitory activity in vivo in an
LPS-induced systemic and ocular complement activation
model in C57Bl/6 mice expressing human CFD [26].
Novartis have also developed orally bioavailable SM inhibi-
tors of CFB; clinical progression of these two molecules is
anticipated. The Achillion CFD inhibitor, ACH-4471, is also
orally bioavailable and is progressing through clinical devel-
opment with announcement of phase 2 studies expected short-
ly [25, 48]. The screening procedure for the Achillion mole-
cule is not published but was likely powered by structure-
guided design, a process central to the company’s drug dis-
covery process. This exciting era where in depth structural
data can augment drug discovery to deliver highly specific
and potent molecules is likely to change the landscape of
complement drug discovery in the coming years. It is intrigu-
ing to speculate that the recently available structures of the
complement inhibitors in complex with their ligands, will also
guide development of SM capable of controlling the activa-
tion complexes of the complement cascade [74, 75].
The examples above illustrate how molecular structure
of a target can guide design of new small molecule entities;
however, prior knowledge of drug binding to target can
also be used to discover new molecular entities of similar
or different modality. RaPharma utilised their mRNA
Extreme Diversity™ display platform to screen for macro-
cyclic peptides which bound to C5. Using this approach,
the company has developed a drug in clinical development,
RA101495, which blocks terminal pathway. This molecule
binds both C5 and C5b and thus blocks MAC formation
triggered by both C5 convertase and by non-complement
serine proteases, such as thrombin and trypsin. Its molec-
ular properties of mass, potency and bioavailability enable
once-daily subcutaneous dosing; it is currently in phase 2
PNH trials at a dose of 0.1–0.3 mg/kg (NCT03030183,
NCT03078582). The crystal structure of RA101495 pep-
tide bound to a functionally relevant domain of C5 provid-
ed sufficient in depth understanding of the inhibitory
mechanism to enable structure-guided optimisation of SM
drugs [76]. These molecules display a differentiated mech-
anism of action compared to anti-C5 monoclonal antibody
therapies and the lead series is reported to be orally bio-
available; data from in vitro functional assays indicate ac-
tivity in whole serum.
Targeting at the genetic level to overcome high
protein concentration
The strategies described above have evolved to overcome
the challenges in complement drug discovery such as target
concentration, target turnover and infection risk. These ap-
proaches which include antibody engineering, targeting of
neoepitopes and development of orally bioavailable mole-
cules are now being validated in the clinic and represent a
huge step forward in complement therapeutics. However,
an alternative line of attack is to modify protein
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biosynthesis by targeting at the genetic level—this might
be to prevent expression of an activating protein or in-
crease expression of an inhibitory protein. Ionis
Pharmaceuticals are leaders in antisense technology and
have developed an array of antisense oligonucleotides
(ASO) targeting translation of complement proteins, in-
cluding CFB; ASO-targeting of CFB reduced levels of cir-
culating CFB (to < 20% normal levels) and improved sur-
vival, proteinuria and renal pathology in murine lupus ne-
phritis [77]. The company also reported that systemic admin-
istration tomice and monkeys of CFBASO impacted levels of
CFB in tissues other than the liver/circulation, such as the eye,
holding promise for therapy of organ-specific disease [78].
The Ionis asset which targets CFB, IONIS-FB-LRx, is cur-
rently in clinical development, although phase 1 data are not
yet reported. Alnylam Pharmaceuticals have developed an
RNAi therapeutics platform for the delivery of siRNAs to
the liver using trivalent GalNAc conjugates and have de-
scribed an asset, ALN-CC5, which silences hepatocyte ex-
pression of C5 following subcutaneous injection. This agent
effectively suppressed liver biosynthesis of C5 in man with a
single dose of 600 mg knocking down C5 levels in plasma by
97% up to day 98 post-treatment; maximum knockdown rel-
ative to baseline was 99% [79]. It is likely that complete
knockdown was unattainable due to extrahepatic biosynthesis
of C5. The first indication in which ALN-CC5 has been tested
is PNH (phase 1/2, NCT02352493), a challenging disease to
treat as experience with eculizumab has taught us that total
knockdown of C5 is required to completely ablate erythrocyte
lysis; however, combination therapy with eculizumab has per-
mitted exploration of potential for reducing dose and frequen-
cy of eculizumab in PNH patients. Whether ALN-CC5 con-
tinues clinical development for PNH remains to be seen, but it
has promise for other indications where complete knockdown
is not essential.
There remains untapped potential for modulating comple-
ment at the genetic level using cell- or gene-targeting strate-
gies [80, 81]. These approaches may enable localised and
long-term expression of additional complement control pro-
teins to provide therapy at sites of disease. This represents an
alternative strategy for localised therapy and for sparing of
systemic complement to minimise risk and side effects.
Increasing the level of control provided naturally by the body
to prevent complement-mediated damage is a sensible strate-
gy. It is notable that man has evolved highly effective mech-
anisms to successfully control complement and maintain
health even in the face of excessive inflammation and infec-
tion; the intricate mechanisms of decay acceleration and co-
factor activities are starting to be unravelled and we may do
well to take heed of lessons of nature and think about how we
might modulate complement (rather than block) to bring about
a healthy balance between activation and control that mini-
mises risk and secondary complications of therapy.
Concluding remarks
Clinical validation with a variety of agents either approved or
in late-stage clinical development has confirmed that
anticomplement therapy can have astounding impact on im-
proving quality of, and preserving, life in a growing number of
diseases. There are limitations to many of the drugs under
development but those shortcomings are driving an evolution
in complement drug discovery which will change the land-
scape for the better. Within the next decade, clinicians will
have at their disposal a toolbox of anticomplement drugs
which can be tailored to the right disease indication to bring
about profound clinical benefit, can be administered at home
by the patients themselves and are available at a cost which
opens access to common diseases and patients worldwide.
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